



[About us](#) [Documents](#) [News](#) [CureWatch Blog](#) [Join us](#) [Donate](#) [Shop](#)

[Home](#) → [CureWatch Blog](#) →

AIDS Cure Study Table

Posted by Katharine Krauss 548.80pc on March 14, 2014 · [Flag](#)

Richard Jefferys of the Treatment Action Group has done the hard work of putting together a useful table of AIDS cure studies. He was assisted in this task by Nelson Vergel (who first organized an online database), Robert Reinhard, and Lynda Dee of AIDS Action Baltimore. We compiled the first-ever list of AIDS cure funders in 2010 for our landmark report, "AIDS Cure Research for Everyone." For future updates from the AIDS Policy Project (not the same as this blog) sign up in the box in the right-hand column of our home page.

Please send any additions or comments on the chart to Richard at the address below--and cc us! Kate@AIDSPolicyProject.org.

Richard Jefferys
 Coordinator, Michael Palm Basic Science, Vaccines & Cure Project
 Treatment Action Group
 261 Fifth Ave., Suite 2110
 New York, NY 10016 USA
richard.jefferys@treatmentactiongroup.org



AIDS Policy Project

A new nation of people who want a cure.

or sign in with [Facebook](#), [Twitter](#) or [email](#).

[Subscribe with RSS](#)

Research Toward a Cure March 11, 2014

Antibodies	ClinicalTrials.gov Identifier(s)	Manufacturer/Sponsor(s)	Phase	Estimated Study Completion Date
3BNC117 (broadly neutralizing monoclonal antibody)	NCT02018510 (not yet open for participant recruitment)	The Rockefeller University	Phase 1	January 2016
Intravenous immunoglobulin in primary HIV infection	No clinicaltrials.gov entry yet. Study name: CHERUB 001	CHERUB (Collaborative HIV Eradication of viral Reservoirs: UK BRC)		
VRC H1MAB060-00-AB (VRC01) (broadly neutralizing monoclonal antibody)	NCT01950325	NIAID	Phase 1	September 2016
Anti-Fibrotic				
ACE inhibitors	NCT01535235	University of California, San Francisco/amfAR	Phase 4	August 2014
Combinations				

DNA/Ad5 vaccine, ART intensification (EraMune02)	NCT00976404 (closed to enrollment)	Vical/GenVec/U.S. National Institutes of Health (NIH) Vaccine Research Center/Objectif Recherche VACCin Sida (ORVACS)	Phase 2	December 2012 (poster presentation at CROI 2014)
SB-728-T, autologous CD4 T cells genetically modified at the CCR5 gene by zinc finger nucleases + cyclophosphamide	NCT01543152	Sangamo BioSciences	Phase 1/2	December 2013
Vacc-4x peptide-based therapeutic vaccine, lenalidomide	NCT01704781	Bionor Immuno AS	Phase 1/2	August 2014
Antiretroviral Therapy in HIV Controllers				
Emtricitabine/rilpivirine/tenofovir	NCT01777997	AIDS Clinical Trials Group/NIAID	Phase 4	May 2017

Gene Therapies	ClinicalTrials.gov Identifier(s)	Manufacturer/Sponsor(s)	Phase	Estimated Study Completion Date
Dual anti-HIV gene transfer construct	NCT01734850	Calimmune	Phase 1/2	June 2015
SB-728-T, autologous CD4 T cells genetically modified at the CCR5 gene by zinc finger nucleases	NCT01252641 (closed to enrollment) NCT01044654	Sangamo BioSciences	Phase 1/2 Phase 1	May 2014 September 2012
Redirected MazF-CD4 autologous T cells for HIV gene therapy (MazF-T)	NCT01787994	Takara Bio/University of Pennsylvania	Phase 1	December 2016
Gene Therapies for HIV-Positive People with Cancers				
Busulfan and gene therapy after frontline chemotherapy in patients with AIDS-related non-Hodgkin lymphoma	NCT01961063 (not yet open for participant recruitment)	City of Hope Medical Center	Not listed	October 2030

Genetically modified peripheral blood stem cell transplant in treating patients with HIV-associated non-Hodgkin's or Hodgkin's lymphoma	NCT01769911 (not yet open for participant recruitment)	Fred Hutchinson Cancer Research Center	Not listed	February 2019
Latency-Reversing Strategies				
vorinostat (SAHA)	NCT01365065 (closed to enrollment) NCT01319383	Merck/University of North Carolina at Chapel Hill/NIAID/Bayside Health	Phase 2 Phase 1/2	March 2016 February 2013
disulfiram (Antabuse)	NCT01944371	University of California, San Francisco/Monash University/amfAR	Phase 1/2	August 2014
panobinostat	NCT01680094 (closed to enrollment)	University of Aarhus/Massachusetts General Hospital/Monash University/Karolinska Institutet/Novartis/amfAR	Phase 1/2	December 2013
romidepsin	NCT01933594 (not yet open for participant recruitment)	NIAID/ACTG/GILEAD	Phase 1/2	January 2015
Stem Cell Transplantation	ClinicalTrials.gov Identifier(s)	Manufacturer/Sponsor(s)	Phase	Estimated Study Completion Date
Allogeneic transplant in individuals with chemotherapy-sensitive hematologic malignancies and coincident HIV infection (BMT CTN 0903)	NCT01410344	National Heart, Lung, and Blood Institute (NHLBI)/National Cancer Institute (NCI)/ Blood and Marrow Transplant Clinical Trials Network	Phase 2	November 2015
Cord blood transplantation using CCR5-Δ32 donor cells for the treatment of HIV and underlying disease (IMPAACT P1107)	No clinicaltrials.gov entry yet. Study name/link: IMPAACT P1107	NIAID/ The Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)		
Therapeutic Vaccines				
GTU-multiHIV, LIPO-5 (DNA + lipopeptide therapeutic vaccines)	NCT01492985	French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis	Phase 2	January 2017

		(Inserm-ANRS)		
VAC-3S therapeutic vaccine	NCT02041247	InnaVirVax	Phase 2	May 2015
AGS-004 (personalized therapeutic vaccine utilizing patient-derived dendritic cells and HIV antigens)	NCT02042248 (not yet open for participant recruitment)	University of North Carolina, Chapel Hill/ Argos Therapeutics/NIH	Phase 1/2	January 2016
Tat Oyi vaccine	NCT01793818	Biosantech	Phase 1/2	June 2015
THV01 lentiviral vector-based therapeutic vaccine	NCT02054286 (closed to enrollment)	Theravectys S.A.	Phase 1/2	November 2014
ChAdV63.HIVcons, MVA.HIVconsv vaccines	NCT01712425 (closed to enrollment)	IrsiCaixa/Fundació Lluita contra la SIDA/Hospital Clinic of Barcelona/ HIVACAT/University of Oxford	Phase 1	April 2015
D-GPE DNA vaccine and M-GPE MVA vaccine	NCT01881581	Centers for Disease Control and Prevention, China	Phase 1	August 2014
HIVAX lentiviral vector-based therapeutic vaccine	NCT01428596	GeneCure Biotechnologies	Phase 1	December 2013
MAG-pDNA, rVSV _{IN} HIV-1 Gag (HIV-1 multiantigen DNA vaccine, human IL-12 DNA adjuvant, recombinant vesicular stomatitis virus Indiana HIV Gag vaccine)	NCT01859325	NIAID/Profectus Biosciences, Inc.	Phase 1	November 2016
Treatment Intensification	ClinicalTrials.gov Identifier(s)	Manufacturer/Sponsor(s)	Phase	Estimated Study Completion Date
maraviroc	NCT00795444	Fundacion para la Investigacion Biomedica del Hospital Universitario Ramon y Cajal/Pfizer	Phase 2	September 2013
Peg-Interferon-a2b	NCT01935089	University of Pennsylvania/The Wistar Institute	Phase 2	July 2016
alpha interferon intensification	NCT01295515	NIAID	Phase 1/2	January 2016

Observational Studies	ClinicalTrials.gov Identifier(s)	Manufacturer/Sponsor(s)	Phase	Estimated Study Completion Date
Establish and characterize an acute HIV infection cohort in a high risk population	NCT00796146	South East Asia Research Collaboration with Hawaii/Armed Forces Research Institute of Medical Sciences, Thailand/Thai Red Cross AIDS Research Centre	N/A	July 2019
Prospective HIV chemotherapy cohort study (CHERUB 003)	NCT01902693	Imperial College London/CHERUB	N/A	January 2015
Tissue drug levels of HIV medications	NCT01490346	University of Minnesota - Clinical and Translational Science Institute/NAID	N/A	December 2013
Towards HIV functional cure (ULTRASTOP) - antiretroviral treatment interruption	NCT01876862 (not yet open for participant recruitment)	Objectif Recherche Vaccins SIDA/Fondation Bettencourt-Schueller	N/A	December 2015

Completed Studies	ClinicalTrials.gov Identifier(s)	Manufacturer/Sponsor(s)	Phase	Available Results
Combinations				
Antiretroviral intensification +/- interleukin-7	NCT01019551	Objectif Recherche Vaccins SIDA (ORVACS)/Cytheris SA/Merck Sharp & Dohme Corp./Pfizer	Phase 2	CROI 2013, Abstract D-1003 (available via NATAP)
MVA-B + disulfiram	Not entered in clinicaltrials.gov	Hospital Clinic of Barcelona/HIVACAT	Phase I	AIDS Vaccine 2013, Poster P04.12
Gene Therapies				
SB-728-T, autologous CD4 T cells genetically modified at the CCR5 gene by zinc finger	NCT00842634	Sangamo Biosciences/ University of Pennsylvania	Phase 1	CROI 2012, Abstract 155 (available via

nucleases				NATAP)
Latency-Reversing Strategies				
disulfiram (Antabuse)	NCT01286259	University of California, San Francisco/Johns Hopkins University/amfAR	Not specified	Clin Infect Dis. (2014) 58 (6): 883-890.
valproic acid	NCT00289952	McGill University/Canadian Foundation for AIDS Research/CIHR Canadian HIV Trials Network	Phase 2	HIV Med. 2012 May;13(5):291-6. PLoS ONE 5(2): e9390.
	NCT00614458	University of North Carolina, Chapel Hill/NIAD/Abbott/Merck	Phase 2	
	NCT00312546	Sharp & Dohme Corp University of North Carolina, Chapel Hill	Phase 1	
Therapeutic vaccines				
MVA-B	NCT01571466	Hospital Clinic of Barcelona	Phase 1	AIDS Vaccine 2013, Poster P04.37 LB

Do you like this post?

[Tweet](#)

Be the first to comment

[Post your comment](#)

[Review the site rules](#)